LuxPark
Luxembourg Parkinson’s Study
The Luxembourg Parkinson’s Study is a cohort study that aims to improve the understanding of Parkinson’s disease and related movement disorders. By following people with Parkinson’s disease, atypical parkinsonism, and healthy volunteers over time, researchers seek to better understand how these conditions develop and progress, and why they affect people differently. The study combines detailed clinical assessments with genetic, biological, environmental, and digital health data to identify early markers of disease, improve diagnosis, monitor disease progression, and support the development of more personalised treatments. As one of Luxembourg’s flagship Parkinson’s research programmes, it also contributes to international efforts to advance research and improve care for people living with Parkinson’s disease.
About the study
Locations
L-1210 Luxembourg
Contact
Ready to take part?
Our team is available to answer all your questions before you decide.
LuxPark is part of the NCER-PD programme
Who can participate?
The LuxPark study is currently recruiting only participants with parkinsonism.
Eligible participants
You may be eligible to participate as a patient if you:
- You may be eligible to participate as a patient if you:
- Are 18 years of age or older.
- Have recently been diagnosed with Parkinson’s disease or another form of parkinsonism within the last 3 years.
- Are able to provide informed consent, or, if your decision-making capacity is limited, have a legally authorised representative who agrees to your participation.
Exclusion criteria
You may not be eligible to participate if you:
- Are pregnant.
- Do not wish to provide the essential data and biological samples required for the study.
- Are currently receiving active treatment for cancer.
The study team will review your medical history and confirm whether you meet the eligibility criteria before enrolment
Not sure about eligibility?
The study team will review each case individually to determine eligibility. If you are unsure whether you are eligible, do not hesitate to contact us.
What will participants do?
01.
Attend an annual study visit
During this visit, you will meet with a neurologist and undergo a neurological examination.
02.
Complete questionnaires and cognitive assessments
These will evaluate your memory, thinking, mood, and other aspects of your health.
03.
Provide biological samples
Blood, urine, and saliva samples will be collected during your annual visits.
04.
Allow researchers to access to relevant medical information
This includes your medical records and any brain imaging performed as part of your routine care.
05.
Provide additional biological samples (optional)
These may include hair, stool, nasal samples, skin biopsies, cerebrospinal fluid, or tissue collected during a medically indicated colonoscopy. These samples are voluntary and will only be collected with your separate consent.
06.
Participate in digital assessments (optional)
Wearable sensors will be used to measure movement and walking. These assessments help researchers better understand how Parkinson’s disease progresses over time.
Where we are currently
Around
2,000
participants
to date
over
50,000
sample tubes collected
To date, around 2,000 people have participated in LuxPark. Individual characteristics of the disease, such as symptoms, other clinical signs, and disease progression, have been systematically recorded and documented alongside a structured sample collection. In total, more than 50,000 sample tubes have been collected, supplemented by countless other data points. The data and samples collected over a ten-year period have already led to numerous scientific publications and now form the basis for many new studies.
By combining clinical and molecular data with information from innovative digital devices and patients’ experiences, scientists can better understand how the disease affects daily life and develop tailored interventions. Some participants even qualify for clinical trials as part of the research and can thus gain access to new treatments that are not yet available on the market.
Contact & location
Luxembourg Research Clinic (LRC)
6, Rue Nicolas-Ernest Barblé,
L-1210 Luxembourg
Study team
Prof. Dr Rejko Krüger
Coordinator, National Centre for Excellence in Research on Parkinson’s disease (NCER-PD); Director of Neurology, Luxembourg Research Clinic (LRC), Luxembourg Institute of Health (LIH); Neurologist and Medical coordinator, Réseau de Compétences Maladies Neurodégénératives, Centre Hospitalier de Luxembourg (CHL); Professor for Clinical and Experimental Neuroscience, University of Luxembourg (UL)
Centre Hospitalier de Luxembourg (CHL)
Dr Manon Gantenbein
Head of Clinical and Epidemiological Investigation Center and Head of Clinical Project Management Office
Luxembourg Institute of Health (LIH)Participating institutions
Funded by
Luxembourg National Research Fund (FNR)
Want to learn more about the study?
Visit the website for full study details, scientific publications and research background.
Ready to take part?
Our team is available to answer all your questions before you decide.
Related news & updates
Small country, significant capacity
Luxembourg may be one of Europe’s smallest countries, but the Luxembourg Research Clinic demonstrates how its highly connected national network…
Landmark agreement ensures sustainability of Luxembourg Parkinson’s programme
Three leading researchers have joined the LRC's scientific committee, bringing expertise in immunology, rare diseases, and translational genomics from institutions…
Related events
Clinical Research Luxembourg Conference
Why does clinical research matter today in Luxembourg? Clinical research plays a vital role in improving patient care, driving medical…